Newsfiscal.ai
Kyverna Therapeutics Presents Updated Phase 1 Data for Miv-cel in Progressive Multiple Sclerosis
· Published
Article summary
Kyverna Therapeutics announced updated results from an investigator-initiated Phase 1 trial of its lead CAR T-cell therapy candidate, miv-cel, in patients with progressive multiple sclerosis.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…